CN114786631A - Stimulation method for eye treatment - Google Patents
Stimulation method for eye treatment Download PDFInfo
- Publication number
- CN114786631A CN114786631A CN202180006284.3A CN202180006284A CN114786631A CN 114786631 A CN114786631 A CN 114786631A CN 202180006284 A CN202180006284 A CN 202180006284A CN 114786631 A CN114786631 A CN 114786631A
- Authority
- CN
- China
- Prior art keywords
- stimulation
- thermal stimulation
- stimulus
- thermal
- pupil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000638 stimulation Effects 0.000 title claims abstract description 154
- 238000011282 treatment Methods 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 38
- 210000001872 metatarsal bone Anatomy 0.000 claims abstract description 50
- 230000017531 blood circulation Effects 0.000 claims abstract description 45
- 230000028327 secretion Effects 0.000 claims abstract description 22
- 210000001747 pupil Anatomy 0.000 claims abstract description 19
- 102000018997 Growth Hormone Human genes 0.000 claims abstract description 10
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 10
- 239000000122 growth hormone Substances 0.000 claims abstract description 10
- 230000015654 memory Effects 0.000 claims description 14
- 229940088597 hormone Drugs 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 150000002739 metals Chemical class 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 239000002390 adhesive tape Substances 0.000 claims description 4
- 239000000919 ceramic Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 208000001491 myopia Diseases 0.000 claims description 4
- 230000004379 myopia Effects 0.000 claims description 4
- 201000010041 presbyopia Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 3
- 201000009310 astigmatism Diseases 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 abstract description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 40
- 238000010438 heat treatment Methods 0.000 description 38
- 210000001508 eye Anatomy 0.000 description 31
- 238000001467 acupuncture Methods 0.000 description 23
- 229960000890 hydrocortisone Drugs 0.000 description 20
- 210000005036 nerve Anatomy 0.000 description 17
- 230000035882 stress Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 13
- 230000036757 core body temperature Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 11
- 208000008589 Obesity Diseases 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 239000004382 Amylase Substances 0.000 description 9
- 102000013142 Amylases Human genes 0.000 description 9
- 108010065511 Amylases Proteins 0.000 description 9
- 235000019418 amylase Nutrition 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000002889 sympathetic effect Effects 0.000 description 9
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 8
- 102400000739 Corticotropin Human genes 0.000 description 8
- 101800000414 Corticotropin Proteins 0.000 description 8
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 8
- 229960000258 corticotropin Drugs 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 210000000467 autonomic pathway Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000000707 wrist Anatomy 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 6
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 210000001255 hallux Anatomy 0.000 description 6
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 6
- 210000001685 thyroid gland Anatomy 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 210000000695 crystalline len Anatomy 0.000 description 5
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 4
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 4
- 102000016267 Leptin Human genes 0.000 description 4
- 108010092277 Leptin Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004404 adrenal cortex Anatomy 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 229940039781 leptin Drugs 0.000 description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005485 electric heating Methods 0.000 description 3
- 210000003811 finger Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 230000005965 immune activity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000627 locus coeruleus Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000002438 stress hormone Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000004873 systolic arterial blood pressure Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 1
- 241000411545 Punargentus Species 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 108010046780 hydrocortisone receptor Proteins 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008345 muscle blood flow Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000037000 normothermia Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 238000010248 power generation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000453 second toe Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 208000013021 vision distortion Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/007—Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0001—Body part
- A61F2007/0002—Head or parts thereof
- A61F2007/0004—Eyes or part of the face surrounding the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0093—Heating or cooling appliances for medical or therapeutic treatment of the human body programmed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0095—Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator
- A61F2007/0096—Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator with a thermometer
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Finger-Pressure Massage (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
The present invention relates to a method for ocular treatment, comprising the steps of: providing a guide element on a specific site of an individual, the specific site including (1) a site where a vertical line of the medial malleolus intersects an extension line of the medial border on the 1 ST and 2 nd metatarsals, (2) a pupil of the left or right eye, (3) the ST36 acupoint of the left or right leg, and (4) the SP acupoint; and controlling the temperature of the guide member within a range of 40 to 50 + -5 ℃, thereby applying thermal stimulation to the respective specific portions, increasing blood flow by 60% or more, and promoting secretion of growth hormone by the subject.
Description
Technical Field
The present invention relates to a stimulus applying apparatus and a stimulus method for treating various conditions, diseases, disorders or symptoms, and more particularly, to a stimulus applying apparatus and a method for promoting secretion of growth hormone of an individual by applying a stimulus, such as a thermal stimulus, to a specific site on a body surface of the individual.
Background
U.S. patent No. 5,950,635 discloses an acupoint surface stimulation method according to a specific acupuncture treatment for reducing anxiety (e.g., stress). This patent discloses that LR3, HT3, and PC6 were assigned to the stimulation points of patients. The electrodes are contacted with the three stimulation points, respectively, thereby passing a current through the electrodes. Here, LR3 was located on the top of the foot, 2cm proximal to the first and second toe edges.
HT3 is located on the medial side of each elbow, midway between the inner end of the elbow crease and the medial epicondyle when the elbow is fully flexed. PC6 was located on each wrist 2cm proximal to the midpoint of the wrist fold, between the tendons of the palmaris longus and flexor carpi radialis. In this patent, the P1 potential is concentrated in at least one subcortical source, specifically, in the podophyllotonic nucleus (PPN), the cholinergic branch of the reticuloendothelial activation system. That is, the patent discloses that when the above-mentioned stimulating acupuncture points (LR3, HT3 and PC6) are stimulated by a needle, the P1 potential is lowered and anxiety is reduced. In addition, no stimulation points to be stimulated by a needle are disclosed, except for stimulation points LR3, HT3, and PC 6. However, this patent discloses that anxiety is reduced by a decrease in the potential of P1 that is concentrated in the nucleus podocarpi (PPN). However, it does not disclose that due to the reduction of anxiety, it is possible to achieve the following: such as normalization of blood pressure, pressure regression, increased body temperature, regression of neutral fat, cholesterol regression, and improvement of blood glucose levels due to remission of insulin resistance.
Disclosure of Invention
Through earnest research efforts, the present inventors have found that a specific stimulation region where psychological stress is released by acupuncture or heat stimulation to a specific stimulation region of the body surface can improve various conditions, diseases, disorders or symptoms, including diabetes caused by stress, and lifestyle-related diseases such as obesity and hypertension.
In one embodiment of the present invention, a method for ocular treatment by applying stimulation to a specific site of an individual with a stimulation application device comprises the steps of: providing two or more guide members made of two different kinds of metals on specific sites including (1) a site where a vertical line of a medial malleolus intersects with an extension line of a medial edge on a 1 ST metatarsal (OS metasale primum) and a 2 nd metatarsal, (2) a pupil of a left or right eye, (3) an ST36 hole of a left or right leg, and (4) an SP hole where a vertical line extending from a center of the pupil intersects with a horizontal line extending at an intermediate height between a lowest part of a nose and a highest part of an upper lip, respectively; and controlling the temperature of the guide member within a range of 40 to 50 + -5 deg.C, thereby applying thermal stimulation to the specific part according to a thermal stimulation pattern so as to increase blood flow of the individual by 60% or more through the application.
The stimulation of the pupil can be performed by taping one of the guide elements to the skin over the center of the pupil while closing the eye. The stimulus may be at least one of a thermal stimulus, a light stimulus, and a vibration stimulus. Ocular treatments may be performed to accelerate the metabolism of the lens of the eye. Ocular treatments can promote the secretion of growth hormone in individuals with reduced hormone secretion with age, while stimulating the outer membrane of the lens of the eye. The ocular treatment may be a treatment of at least one of cataract, presbyopia, myopia, and astigmatism.
In another embodiment of the present invention, the method may comprise the steps of: storing the thermal stimulation pattern in a memory unit; placing two or more guide elements on at least two different specific locations of the specific locations (1) to (4), respectively; reading out the thermal stimulation pattern from the memory cell; controlling the temperature of the two or more guide elements within the range of 40 to 50 ± 5 ℃; and outputting the thermal stimulation pattern to the two or more guide members, whereby thermal stimulation is simultaneously applied to the respective specific sites according to the thermal stimulation pattern so as to increase blood flow by 60% or more by applying the thermal stimulation.
In one embodiment, the method of promoting growth hormone secretion as described above further comprises the step of measuring blood flow rate by laser Doppler (Doppler) tissue flow meter.
In the present invention, the stimulus of the thermal stimulus pattern formed by controlling the electric heating means is not simultaneously and independently applied to at least one region selected according to the condition of the disease, thereby achieving a reduction in psychological stress, an increase in core body temperature, a reduction in neutral fat, a reduction in cholesterol, an improvement in blood glucose level due to the relief of insulin resistance, and an inhibition of arteriosclerosis.
Drawings
Other features and advantages of the stimulation method of the invention for releasing pressure and of the method of pressure releasing medical treatment using the same will be apparent from the ensuing description, taken in conjunction with the accompanying drawings, in which:
FIG. 1 is a schematic view of an electric heating apparatus for use in the present invention;
FIG. 2 is a schematic diagram of an electrical circuit diagram of an electrical heating apparatus;
FIG. 3 is a schematic diagram of a thermal stimulus waveform obtained by controlling an electric heating device;
fig. 4 is a schematic view of an area of a sole to be stimulated, wherein "x" shows between the 1 st and 2 nd metatarsal bones, "y" shows between the 2 nd and 3 rd metatarsal bones, and "z" shows a portion where a vertical line of the medial malleolus intersects an extension line of the medial edge on the 1 st and 2 nd metatarsal bones;
FIG. 5 is a schematic of a thermal stimulation protocol;
FIG. 6 is a schematic view of an area proximate to the thyroid to be stimulated;
FIG. 7 is a schematic view of a toe area of a leg to be stimulated;
FIG. 8 shows the sites (L), (K), (M) as specific stimulation areas to be stimulated;
FIG. 9 shows the infraorbital artery of the right eye, as seen from above the eye, and the view of the eye and the superior wall of the infraorbital nerve tube open;
fig. 10 is a front view of an individual's face showing more stimulation sites.
Detailed Description
In the stimulation treatment method according to the present invention, there is a stimulation treatment method for applying stimulation to a specific region to be stimulated at a body surface by a stimulation application apparatus so as to increase a blood flow rate by 60% or more, preferably 100% or more, thereby providing medical treatment, in which the blood flow rate is measured by laser doppler tissue blood flow meter connected to a central portion of the inner side of a wrist joint.
The specific region is at least one region selected from the group consisting of: the portions where the vertical lines of the 1 st and 2 nd metatarsal bones, the 2 nd and 3 rd metatarsal bones, and the medial malleolus intersect with the extension line of the medial edge on the 1 st and 2 nd metatarsal bones at the sole of one of the left and right sides. Another specific area is the area close to the thyroid gland. Another particular area is the area between the outer skin and the horizontal line of the inner boundary portions of the hallux distal phalangeal bottom and proximal phalangeal bones at one sole on the right and left sides.
The stimuli are applied non-simultaneously and independently to at least one area selected according to the condition of the disease.
The stimulus applying device is a thermal stimulus applying device, and the thermal stimulus applying device forms a warm temperature stimulus pattern, wherein the stimulus pattern is composed of a thermal stimulus waveform and intervals, and the thermal stimulus waveform includes a heating waveform obtained by raising a temperature to a peak temperature by heating, 50 ± 5 degrees celsius, and a heat release waveform formed by stopping heating when the peak temperature is reached.
The stimulation is selected from acupuncture and moxibustion needle stimulation, warm temperature stimulation, light stimulation, magnetic stimulation and ultrasonic stimulation.
The stress release treatment method comprises a stimulation method.
The stimulation evaluation method constitutes a stimulation method in which the rate of increase in blood flow is used as an index for stimulation evaluation.
Generally, if pressure is applied to a living organism, both systems will be activated. One of the systems is the sympathetic nervous system, starting from the locus coeruleus (locus coeruleus), where norepinephrine is secreted from nerve endings and epinephrine is secreted from the adrenal cortex.
Other systems include the HPA system (hypothalamic pituitary adrenal axis), in which pituitary gland-releasing hormone (CRH) secreted from the hypothalamus (paraventricular nucleus) acts on the pituitary gland, and adrenocorticotropic hormone (ACTH) secreted from the anterior pituitary gland (adenohypophysis) acts on the adrenal cortex, thereby secreting the final glucocorticoid (cortisol) from the adrenal cortex. Cortisol is considered an index of psychological/physical stress and can also be measured from saliva. In this stimulus, salivary amylase, ACTH and cortisol are reduced. It appears that normalization of the stress response system hormone occurred.
Cortisol controls carbohydrate, fat and protein metabolism and is an essential hormone for living organisms. Blood pressure and blood glucose levels rise depending on their number secreted by pressure, and they affect various biological functions in vivo, such as, for example, the immune system (inflammatory suppression), the blood circulation system, and the metabolic system (sugar regeneration) (glucose neogenesis), which lead to a decline in immune function. In addition, cortisol receptors are present in the hypothalamus, hippocampus, and pituitary, and if the secretion amount of cortisol increases, the synthesis amount of CRH or ACTH decreases. Thus, cortisol secretion is inhibited. In addition, in recent years, MRI and the like have been reported in an exponential fashion on the basis of the brain of a patient suffering from posttraumatic stress disorder (PTSD), in which the hippocampus is atrophied when cortisol is secreted excessively due to excessive stress. Thus, cortisol also affects the central system (cognition, memory, emotion), and dementia and the like can be expected to be prevented by using acupuncture needle stimulation.
The substance that draws attention with cortisol is DHEA. DHEA is a steroid hormone secreted from the adrenal cortex, like cortisol. The effect is reported to be opposite to that of cortisol. For example, while cortisol inhibits Th1 immune activity (NK cells, killer T cells) and promotes Th2 immune activity (B cells), DHEA in turn promotes Th1 immune activity. Furthermore, it is believed that patients with depression have high cortisol levels and low DHEA levels, and that the ratio (cortisol/DHEA ratio) is crucial. DHEA is considered to be a hormone that well regulates the action of cortisol.
In addition, DHEA sulfate (DHEA bound via sulfate groups: DHEAS) (sulfate group bound form) is also considered critical. Unlike cortisol, there is no negative feedback on DHEA, and if it is secreted, it becomes DHEAs and accumulates for a relatively short time. Although DHEAS itself does not have activity as a hormone, DHEAS becomes DHEA in the organ serving as a target, and acts on the target organ. DHEAS was taken as an index showing the steady state of DHEA. DHEA and DHEAs are considered to have a pressure-dependent relationship.
It is believed that there are mechanisms due to vasodilation and mechanisms underlying the influence of such stimulation on sympathetic nerves. Vasodilation is thought to increase production of calcitonin gene-related peptide (CGRP) by stimulation. It is believed that when nerves and the like are stimulated, the release of CGRP and the like increases due to the increase in muscle blood flow. That is, efferent autonomic or motor nerves are not included in the dorsal root of the spinal nerve. It is thought that the axon reflex mechanism is generated due to stimulation of afferent nerves and the like, and CGRP is released from its terminal end, and it is a mechanism based on vasodilation of the control region.
Furthermore, it is also assumed that an influence on the autonomic nervous activity of the control blood vessels is exerted. The blood vessels of the muscles are controlled by adrenergic sympathetic nerves and cholinergic sympathetic nerves. The former constricts nerves via the blood vessels of alpha-receptors, and the latter dilates nerves via the blood vessels of acetylcholine. It is said that the former acts on the blood vessels of the muscles in their tense state all the time even in the resting state, so that the blood vessels are maintained in a constricted state all the time to some extent. On the other hand, with respect to the latter, it is considered that the striationless muscle of the blood vessel relaxes in response to the release of acetylcholine from nerve terminals, so that the blood flow increases.
Since the chronic sympathetic debilitating state is improved when the parasympathetic nerve dominance is maintained by the acupuncture needle or warm-temperature heating stimulation, it is considered that inhibition of the renal RA system may be promoted. This improves QOL in hypertensive patients.
In addition, continuous stimulation treatments such as acupuncture needles and warm-temperature heating show a tendency of insulin reduction. It is believed to be based on a sustained improvement in insulin resistance rather than a temporary increase in insulin secretion. Furthermore, obesity is one of the most important risk factors for IGT. Harris et al epidemiologically showed a relationship between IGT and DM and obesity, with the degree of obesity and weight gain playing a major role in the pathogenesis of DM. Thus, it is believed that ameliorating the obesity problem results in the prevention of DM as well as hypertension. In the medical visit, an average monthly weight loss of about 2 kg was demonstrated.
In addition, considering the increase in the core body temperature, blood pressure changes, and the like, it is considered that stimulation such as acupuncture needles, warming, and the like regulates the blood flow of each organ via systemic blood pressure and autonomic nerves. Acupuncture is believed to exert an effect on systemic blood pressure, i.e., acupuncture acupuncturing elicits a systemic response via sympathetic nerves.
Blood flow on living tissue was measured using a laser doppler tissue flow meter ALF21D (manufactured by Adovans). In the laser doppler tissue flow meter ALF21D, when a living tissue is irradiated with a semiconductor laser light (whose wavelength is 780nm), light reflected from the tissue is converted into an electric signal and the electric signal is processed, thereby obtaining information of a blood flow volume.
A C-type laser probe (diameter 10mm, thickness 3mm, laser irradiation area 2 mm) of a laser Doppler tissue blood flow meter was used2And a measurement depth of 1mm) was attached to the center portion of the wrist level line, and measured, and left for 15 minutes after stimulation. The warm heating probe is connected between the bones of the second and third metacarpals. And calculating the increase rate of the blood flow according to the measurement of the blood flow.
Regarding the principle of laser doppler tissue flow meter, laser light collides with red blood cells flowing through the inside of a blood vessel, and doppler shift (frequency change) generated upon receiving dispersion is used. The measurement method is characterized by the capability of non-invasive and real-time reaction and continuous measurement. In addition, ALF21D used this time was able to display blood flow on the order of ml/min/100 g. This is because the signal processing is based on the Bonner et al theory.
The mechanism of the increase in blood flow in pressure release therapy will be described below. Mental stress of a living body stimulates sympathetic nerves via the limbic system of the brain and the hypothalamus-pituitary gland, thereby causing vasoconstriction and damage to the microcirculatory system including internal organs of the living body. In "stress release therapy" in response to a blood flow reduction response, an increase in body temperature of the peripheral subcutaneous portion at distances of 3mm and 5mm has been confirmed, and secretion control of stress hormones (amylase, cortisol, and ACTH) has been confirmed.
In addition, Vasoactive Intestinal Peptide (VIP), which is a bioactive hormone, accelerates the motility of Intestinal tracts secreted from the digestive tract, pancreas, and hypothalamus, and increases the blood flow including the digestive tract tubes. In addition, Vascular Endothelial Growth Factor (VEGF) accelerates the vascularization and vascular permeability of the microvasculature. It is considered that since VIP and VEGF are significantly increased by "stress release therapy", the action of VIP and VEGF is induced, so that the blood flow of the visceral and peripheral blood streams is increased.
From these results, it is considered that "stress release therapy" by thyroid stimulation acts incrementally on hypothalamic innervation in terms of the sympathetic nerve activity and the hypothalamic pituitary gonadotropin hyperresponse to the living body by the stress stimulation through autonomic nerves, and that the blood flow is increased through VIP and VEGF while the release of the stress hormone is suppressed.
In addition, if harmful stimuli such as pressure and pain are added to a living body, blood flow volume of fingertip skin decreases, and a non-sympathetic nerve flow response (SFR) occurs. This response is assessed by an index based on peripheral blood flow as a response to noxious stimuli via the sympathetic nervous system. In pressure release therapy, blood flow at the central part of the wrist level is increased according to laser doppler tissue blood flow meter, and it appears that blood flow reduction through pressure mediated Sympathetic Flow Response (SFR) increases blood flow through VIP and VEGF through "pressure release therapy" and inhibition of pressure hormones.
Fig. 1 is a schematic view of an electric warm-temperature heating apparatus used in the present invention. Fig. 2 is a schematic diagram of a circuit diagram of an electric warm-temperature heating device.
The electric warm-temperature heating device comprises a device 10 and a guiding element 14 for thermal stimulation, which is connected to the device 10 by a lead 12.
As shown, the apparatus 10 includes: a memory unit 16 in which a thermal stimulation pattern is stored; a control unit (CPU)18 that reads out a thermal stimulation pattern from the memory unit 16; and an output unit 20 supplying the thermal stimulation pattern to the guide element 14 for thermal stimulation. The thermal stimulus is applied to the portion to be stimulated according to a thermal stimulus pattern.
A control unit (CPU)18 is connected to the memory unit 16. A thermal stimulation pattern for obtaining an equivalent to the stimulation condition obtained by the moxa burning is stored in the memory unit 16. A control unit (CPU)18 reads out the thermal stimulation pattern from the memory unit 16, controls the output to the one or more heating elements based on the detection of the temperature sensor 22, and outputs the thermal stimulation pattern to the one or more guiding elements for thermal stimulation.
The device 10 is connected to two or more guiding elements for thermal stimulation in order to supply a thermal stimulation pattern to at least two different areas to be stimulated. In this way, a thermal stimulation pattern is applied to the area to be stimulated via the guiding elements for thermal stimulation.
The temperature sensor 22 is disposed at a location related to the temperature of the affected area in the vicinity of the heating element. The guide element for the thermal stimulation has the structure set forth below. The guide element 14 for thermal stimulation comprises the housing of the device 10; a heater disposed in the housing, the heater serving as a source of warm-temperature heating for applying the thermal stimulus; a heat conduction plate disposed on the lower surface of the housing and conducting heat of the heater to the skin of the patient; and a sealing plate disposed on an upper surface of the housing.
The heat conducting plate for the guiding elements for thermal stimulation, which is intended to be placed on two different areas, is advantageously made of at least two different kinds of metals. In this embodiment, aluminum and steel are used.
The temperature sensor is disposed in a predetermined position of the housing in contact with a portion of a human body, and detects a temperature of the position so as to transmit a detection signal to the sense amplifier. A control unit (CPU) controls an output of the power generation circuit so that a temperature of a portion in contact with a skin surface of the human body contact may not exceed a predetermined temperature. In the warm-temperature heating apparatus, the surface temperature of the guide member for thermal stimulation is controlled to be in the range of 40 to 50 ± 5 degrees celsius.
When the heating temperature of the heating element detected by the temperature sensor is equal to or lower than the reference temperature, the positive side period of the pulse signal is controlled to be longer and the negative side period of the pulse signal is controlled to be shorter according to the output of the temperature sensor. In contrast, when it is in a state of the reference temperature, its positive side period is controlled to be short, and its negative side period is controlled to be long.
Fig. 3 shows a desired thermal stimulus waveform, which is obtained by controlling an electric warm-temperature heating apparatus. The thermal stimulation waveform includes a heating waveform 2 obtained by heating it to a predetermined peak temperature (e.g., 50 ± 5 degrees celsius), and a thermal release waveform 3 formed by stopping heating after it reaches the peak temperature.
The heating waveform may be a convex heating waveform, an upwardly-sloped heating waveform, or a concave heating waveform. Further, the heating waveform is not limited to the above-described heating waveform. It may be a saw-tooth waveform or a concave-convex waveform. In addition, the heating waveform and the heat release waveform may be formed as a sine waveform.
The cyclic pattern of thermal stimulation includes a thermal stimulation waveform consisting of a warm heating waveform and a heat release waveform, and an interval before the next warm heating curve. A cycle pattern of the thermal stimulation is preferably set so that the thermal stimulation region may be 1 second to 30 seconds, and the interval between the heating regions may be 1 second to 10 seconds.
The thermal stimulation patterns preferably include independent thermal stimulation waveforms that are phase shifted such that the thermal stimulation patterns do not substantially overlap one another. That is, as shown in the figures, the thermal stimulation pattern includes a first thermal stimulation pattern that includes a spacing between one thermal stimulation region and the next; and a second thermal stimulation pattern including a thermal stimulation region for a certain period of an interval of the first thermal stimulation pattern and an interval in the first thermal stimulation region.
The cycling pattern of thermal stimulation is preferably repeated for 10 to 30 minutes. And the cycling pattern of the thermal stimulation is preferably repeated again.
In addition, as the stimulation, in addition to acupuncture stimulation and warm-temperature heating stimulation, light stimulation, magnetic stimulation, ultrasonic stimulation, low-frequency wave stimulation, or the like can be used.
Specific example 1
The subject is adult male and female. In consideration of burn, the electric warm-temperature heating apparatus MXA-8000(SO-257) was used to perform warm-temperature heating stimulation. The probe had a diameter of 10mm and was intermittently subjected to warm-temperature heating stimulation for 15 minutes with a peak value of 50. + -. 5 ℃. The probe is attached to a specific area of the body surface to be stimulated for subsequent warm heating, and the specific area is heated at 40 to 50 degrees celsius.
Here, the specific region is at least one selected from the group consisting of: the portions of the soles of the right and left feet where the vertical lines between the 1 st and 2 nd metatarsal bones, the 2 nd and 3 rd metatarsal bones, or the medial malleolus intersect with the extension lines of the medial edges of the 1 st and 2 nd metatarsal bones (see fig. 4). In fig. 4, "x" shows a region between the 1 st and 2 nd metatarsal bones, "y" shows a region between the 2 nd and 3 rd metatarsal bones, and "z" shows a portion where a vertical line of the medial malleolus intersects with an extension line of the medial edge on the 1 st and 2 nd metatarsal bones.
And depending on the condition of the disease, the warm thermal stimulus is preferably applied non-simultaneously and independently to at least one specific area to be stimulated.
Table 1 shows the results of blood flow measured by using laser doppler tissue flow meter, and the rate of increase of blood flow, before and after stimulation at the central region of the wrist level. Wherein the warm-temperature heating stimulus is applied to at least one selected from the group of: the portions where the vertical lines of the 1 st and 2 nd, 2 nd and 3 rd metatarsal bones or the medial malleolus at the sole of the right and left sides intersect with the extension line of the medial edge on the 1 st and 2 nd metatarsal bones.
TABLE 1
Patient(s) is/are | Before stimulation | After stimulation | Rate of increase |
The 1 st name | 1.287 | 2.1036 | 63 |
The 2 nd name | 3.2791 | 8.0098 | 144 |
|
1.7603 | 2.959 | 68 |
The 4 th name | 2.8101 | 4.6872 | 68 |
Name 5 | 5.9857 | 13.0065 | 117 |
The 6 th name | 3.453 | 6.9631 | 102 |
Name 7 | 2.0954 | 4.7401 | 126 |
The 8 th name | 1.4332 | 3.5227 | 146 |
The 9 th name | 1.0091 | 1.7377 | 72 |
The 10 th name | 3.9592 | 8.0699 | 104 |
The 11 th name | 1.5635 | 3.8743 | 148 |
As shown in table 1, the therapeutic effect is significant when the increase rate of blood flow is 60% or more and preferably 100% or more. At least one specific area to be stimulated is selected that is different from each other. The rate of increase in blood flow is used as an indicator of stimulation. The rate of increase in blood flow may be 60% or more, preferably 100% or more. In addition, the rate of increase in blood flow is used as an index for evaluating the stimulation.
Considering the effect on psychological stress via autonomic nerves, after leaving the individual in the supine position for 20 minutes, blood pressure, core body temperature, salivary amylase and HEARTRATER (arterial age) were measured, and only warm-temperature stimulation was performed for 15 minutes, and again immediately after stimulation.
The protocol for thermal stimulation is shown in figure 5. One treatment was performed and the measurements were taken before, after and the following day. The pre-capillary circulation dominated by the autonomic nervous system was measured by a deep-layer thermometer (deep-layer thermometer, CORE TEMP CM-210 manufactured by TERUMO corporation), and the psychological stress was measured by DAEKI AMY (salivary amylase monitor manufactured by NIPRO). In addition, the arteriosclerosis index and the vascular age were quantified by HEARTRATER.
Blood was collected twice, i.e., at the same time of day before and after stimulation, and after the day before and 9:00PM on test day, the individual had no food or liquid to eat except water.
Furthermore, the interpretation work was done in advance, so that they did not take a form of strenuous exercise from 24 hours before the test to one day after the test, and were instructed to get home to the laboratory in the morning of the test day (if possible), and avoid strenuous exercise and travel with minimal action.
An increase in temperature at the area to be stimulated is observed. It should be noted that an increase in temperature was observed, especially when the stimulus was applied between the 2 nd and 3 rd metatarsal bones. With respect to salivary amylase, an increasing trend was shown when stimulation was applied between the 2 nd and 3 rd metatarsal bones. Salivary amylase increase (+ 34.25). In addition, cortisol was decreased between the 1 st and 2 nd metatarsals (-3.33), and at a portion where the perpendicular line to the medial malleolus intersects with the extension line of the medial edge on the 1 st and 2 nd metatarsals (-6.33),
when a stimulus was applied between the 1 st and 2 nd metatarsal bones, systolic arterial pressure decreased significantly (-13.00).
When stimulation was applied between the 1 st and 2 nd metatarsal bones, total cholesterol was significantly reduced (-10.33). Neutral fat also decreased at the portion where the perpendicular line to the medial malleolus intersected the extension of the medial border on the 1 st and 2 nd metatarsals (-24.67). With respect to the arteriosclerosis index (a.i.), when a stimulus is applied between the 1 st and 2 nd metatarsal bones, the a.i. decreases (-0.10).
When a stimulus is applied between the 1 st and 2 nd metatarsal bones; or the region between the 2 nd and 3 rd metatarsal bones, blood glucose levels decreased (-5.33 or 5.25). In addition, hemoglobin Alc was also reduced (-0.13) when the stimulation was applied between the 2 nd and 3 rd metatarsal bones.
When a stimulus was applied to a portion where the perpendicular line of the 2 nd and 3 rd metatarsal bones or the medial malleolus intersects with the extension line of the medial edge on the 1 st and 2 nd metatarsal bones, the secretion amount of gastrin as a gastrointestinal hormone was significantly increased (19.33 or 48.67). This indicates increased digestion and absorption, intestinal motility, etc.
Adiponectin increases (+1.5) when a stimulus is applied between the 1 st and 2 nd metatarsal bones. Since adiponectin is considered as one of substances that activate the longevity protein (Sirtuin) gene and is one of genes associated with longevity, it is suggested that two stimuli to two regions of the sole portion open genes associated with longevity.
Leptin is reduced (-0.57 or-0.20) when a stimulus is applied to the portion where the vertical line between the 1 st and 2 nd metatarsal bones or medial malleolus intersects the extension of the medial border on the 1 st and 2 nd metatarsal bones. Leptin is called "ghrelin" and the body can originally store fat in the body. At present, it is said that 95% of obesity is caused by "leptin resistance" due to leptin excess. It is thought that by adjusting the amount of secretion of this substance, the Dayez effect (Dayez effect) would be expected to occur.
The balance of autonomic nerves is measured by the heart regulators. The activity level of the autonomic nerve increases between the 1 st and 2 nd metatarsal bones (+ 28.33). The degree of impedance of the autonomic nerve increases at positions between the 1 st and 2 nd metatarsal bones (+14.67) and between the 2 nd and 3 rd metatarsal bones (+ 12.25). The pressure index decreased between the 1 st and 2 nd metatarsal bones (-17.00). Fatigue decreased between the 1 st and 2 nd metatarsal bones (-30.00).
Specific example 2
In this embodiment, an example of performing acupuncture stimulation is applied, in which a region near the thyroid is used as a specific region to be stimulated (see fig. 6). The thyroid gland is an internal organ, which is located at a shallow position from the body surface, and is observed at a depth in the range of about 5mm to 30 mm. Therefore, in general, the inspection is performed by using a high-frequency surface probe in the ultrasonic inspection. The thyroid gland has a long diameter of about 40mm to 50mm, a thickness of about 12mm to 18mm, a width diameter of about 15mm to 25mm, and a thickness of its isthmus (isthmus) of about 2mm to 4 mm.
Acupuncture was performed on ten men and women who were diagnosed with hypertension between the ages of 20 and 60 in total. The effect on psychological stress is expected to be mediated by autonomic nerves, and a disposable acupuncture needle (made of stainless steel, 40mm in length and 0.18mm in thickness) is inserted into the anterior cervical region to a depth of 2-3 cm. After allowing the subject to rest in the supine position for 15 minutes, blood pressure, core body temperature, and salivary amylase were measured. And then they were applied with a needle stimulation for 15 minutes and measured again immediately after needle withdrawal. Treatment was performed seven times, i.e., 3 days after the first day, 7 days after it, 10 days after it, 14 days after it, 17 days after it, 21 days after it,
in specific example 2, blood flow can be measured before and after stimulation at the central region of the wrist level by using laser doppler tissue blood flow meter. And the same results as in table 1 of specific example 1 were obtained.
Action
Values for salivary amylase, hypertension and hypotension showed a significant decrease by acupuncture needle stimulation. On the other hand, core body temperature also showed significant elevation at distances of 3mm and 5 mm.
For salivary amylase, an increase was observed as + 35. It is believed that the elimination of these stresses reduces blood pressure, since individuals in hypertensive patients always have higher psychological stress. As acupuncture treatment continues, the systolic arterial pressure and diastolic blood pressure of the individual tend to decrease (-13). It was observed that individuals who were not administered a hypotensive agent had an immediate rise in blood pressure after acupuncture treatment. In individuals with lower core body temperatures at distances of 3mm and 5mm, the deep core body temperature rises greatly (+2), and the core body temperature is observed to generally approach normothermia. In addition, there is a tendency that the core body temperature before the acupuncture treatment becomes high as the acupuncture treatment is continued.
As acupuncture treatment continued, the secretion of cortisol and additionally ACTH as its higher center were significantly reduced immediately after the acupuncture treatment on day zero, and a gentle increase in the secretion of cortisol and ACTH was observed thereafter. Although cortisol and ACTH in all individuals show a transient decrease immediately after acupuncture and then show a gradually increasing trend, a decreasing trend is observed as the treatment continues.
Shows that there is a tendency of a gentle decrease in T-CHOL, HDL-CHOL and LDL-CHOL.
Specific example 3
In this embodiment, a region between the outer skin and a horizontal line on the inner boundary portion of the hallux distal phalanx sole and the proximal phalanx at one sole on the right and left sides of the left foot and/or the right foot is subjected to moxibustion (moxa acupuncture) as a specific region to be stimulated.
In fig. 7, the symbol "∘" shows the specific area to be stimulated between the outer skin and the horizontal line of the inner boundary portion of the hallux distal phalanx bottom and proximal phalanx bone, and the stimulation is applied.
Moxibustion is applied to an individual by using a previously rolled moxa roll (moxa). Moxibustion was continuously performed five times in the area between the outer skin and the horizontal line of the inner boundary portions of the bottom of the distal phalanx and the proximal phalanx of the thumb, respectively, and stimulation was applied.
The moxa stick amount per moxibustion (moxibustion) is 0.002g, and the combustion temperature is 80 + -5 deg.C at the maximum. Two treatments were performed, three times in the beginning and end of the week, for a total of six treatments.
It was confirmed from clinical data that by applying a stimulus to the region between the outer skin and the horizontal line of the inner boundary portion of the hallux distal phalanx sole and proximal phalanx bone, the secretion of thyroid hormone was activated and the stimulus was applied.
In specific example 3, blood flow can be measured before and after stimulation at the center region of the wrist level by using laser doppler tissue blood flow meter. And the same results as in table 1 of specific example 1 were obtained.
Thereby, the core body temperature is raised, and obesity, diabetes and the like are prevented and improved. Thus, this treatment is considered to be one of the effective ways of therapeutic programs for lifestyle-related diseases such as diabetes and obesity. In particular, the following will explain clinical data on elevated core body temperature, showing significant effects on diabetes and obesity.
The explanation was made for a total of nine men and women between the ages of 20 and 60 who were diagnosed with diabetes, obesity and hypertension. The stimulation is applied by moxibustion to the portion between the outer skin and the horizontal line of the inner boundary of the hallux distal phalanx sole and proximal phalanx of the left and/or right foot.
As described above, there are the following effects: core body temperature is increased, neutral fat is reduced, cholesterol is reduced, insulin is reduced, and arteriosclerosis is inhibited.
Preferably at least one of the specific regions to be stimulated selected from the group of: EXAMPLES 1 OR 2 OR
The foregoing description has been presented only to illustrate and describe exemplary embodiments of the present stimulation method for releasing pressure and a method of pressure-releasing medical treatment by the stimulation method. It is not intended to be exhaustive or to limit the invention to any precise form disclosed. It will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims. The invention may be practiced otherwise than as specifically explained and illustrated without departing from its spirit or scope.
Specific example 4
The site of stimulating blood vessels (arteries) and nerves (specific region to be stimulated) is as follows. Fig. 8 shows sites (L), (K), (M) as specific stimulation regions to be stimulated. And fig. 9 shows the infraorbital artery of the right eye, as seen from above the eye, and the view of the eye and the superior wall of the infraorbital nerve tube open. The specific area to be stimulated is the site where blood flow is increased by 60% or more by applying stimulation.
(L) supraorbital foramen notch (occiusaral lesion) site;
the lateral canthus at 1cm height from the orbit.
The supraorbital artery, vein and supraorbital nerve are in the area of the facial branch.
The sites where the blood vessels (arteries) and nerves of the eye are stimulated.
(K) Part(s)
The part where the intersection of the line connecting the inner canthus of the eye and the part (L) and the perpendicular line connecting the outer canthus of the eye is located.
The site of increased blood flow in the artery in the eye.
The site of peripheral nerve stimulation of the eye.
(M) site
The outer canthus on the 1 horizontal finger from the center of the connecting line between the inner ends of the left and right eyebrows.
The site of the pulley that stimulates the eye.
(F) Parts (above)
The intersection of the medial malleolus perpendicular to the plantar 1 st and 2 nd metatarsal on the medial border,
stimulation is selectively applied to sites (L), (K), (M) and (F) to be stimulated.
Stimulation is selectively applied to sites (L), (K), (M) and (F) to be stimulated. One combination of stimulus application sites comprises the following.
Mode 1; (R) L- (L) L- (R) F
Mode 2; (L) L-K- (R) F
Wherein (R) is the right side and (L) is the left side.
The combination of the stimulation application sites is not limited to this combination.
Preferably, stimulation of the site (F) is always provided.
The stimulus is applied to the respective portions by using heat, light, sound waves, vibration, or pressure.
The thermal stimulus is applied by using a thermal stimulation device as mentioned in fig. 1 and 2.
Specific example 5
Fig. 10 is a schematic front view of an individual's face, including face 100, head 102, eyes 104, pupils 103(EY), nose 105, mouth 106, and ears 107.
Exemplary stimulation application sites include the following:
(1): (F) the vertical line of the medial malleolus intersects the extension of the medial edges on the 1 st and 2 nd metatarsals,
(2): (L) incising the upper orbit hole,
(3): ST36 acupoints, an
(4): and (4) SP points.
As explained previously, site (F) is the portion shown in fig. 4, where "x" shows between the 1 st and 2 nd metatarsal bones, "y" shows between the 2 nd and 3 rd metatarsal bones, and "z" shows a portion where the vertical line of the medial malleolus intersects with the extension line of the medial border on the 1 st and 2 nd metatarsal bones, and site (L) is the portion located above the eyes, as shown in fig. 8. The "ST acupoint" is one of the meridian acupoints named by World Health Organization (WHO), wherein the No. 36 gastric acupoint is the thirty-sixth gastric acupoint. This site is called "Zu San Li" (ST36) and is located along the outer boundary of the tibia, four fingers wide down the base of the knee. As shown in fig. 10, the "SP point" is a point where a vertical line "a" extending from the center of the left and/or right eye (the center of the pupil) intersects with a horizontal line "b" extending at an intermediate height between the lowest part of the nose and the highest part of the upper lip. The vertical line "a" may be set to one or each of the left and right eyes to set two SP points.
In the method of promoting secretion of growth hormone by an individual, heat stimulation and/or pressure stimulation is applied to the above specific sites (1) to (4) by using the stimulation application apparatus as disclosed in the present application. Preferably, the stimuli are applied simultaneously to the specific sites (1) to (4).
The stimulus application device has two or more guiding elements made of two different kinds of metals. The guiding element is attached to the specific part. Subsequently, the guiding elements are heated to a temperature of 40 to 50 ± 5 ℃ so that a thermal stimulus is provided to each of the sites.
The stimulus application device may be an electrical warm-temperature heating device which is performed in a controlled manner using a control method as explained above. To increase the effect, the method may comprise the steps of: storing the thermal stimulation pattern in a memory unit; placing two or more guide elements made of two different kinds of metals on at least two different parts of a body surface, respectively; reading out the thermal stimulation pattern from the memory cell; and outputting the thermal stimulation pattern to the two or more guide elements and controlling the temperature of the guide elements within a range of 40 to 50 ± 5 ℃; and applying a thermal stimulus to the site according to a thermal stimulus pattern such that the blood flow rate is increased by 60% or more by applying the thermal stimulus. The method may use any of the configurations or steps disclosed in the present application.
By applying stimulation to specific sites (1) to (4), preferably simultaneously to each of the sites, via the above stimulation process, secretion of growth hormone in the subject can be significantly increased, providing the subject with a variety of benefits, including improved sleep quality, decreased amounts of cholesterol, neutral fat, subcutaneous fat and/or visceral fat, and stabilized blood glucose levels.
Specific example 6
The methods and apparatus disclosed herein may be used for ocular treatments including eye care, such as cataract, presbyopia (presbyopia/managed eyes), myopia/nearsightedness, astigmatism/vision distortion, and the like. Exemplary stimulation application sites for ocular therapy include the following sites, as shown in fig. 10:
(1): (F) the area where the vertical line of the medial malleolus in the left or right foot intersects the extension of the medial border on the 1 st and 2 nd metatarsals,
(2): pupil 103(EY) of left or right eye 104;
(3): ST36 point of left or right leg;
(4): SP point; and any combination of two, three, or four of the above.
As explained previously, site (F) is the portion shown in fig. 4, where "x" shows between the 1 st and 2 nd metatarsals, "y" shows between the 2 nd and 3 rd metatarsals, and "z" shows the portion where the vertical line of the medial malleolus intersects the extension line of the medial edge on the 1 st and 2 nd metatarsals, and site (L) is the portion located over the eyes, as shown in fig. 8. The "ST acupoint" is one of the meridian acupoints named by the World Health Organization (WHO), with the No. 36 stomach acupoint being the thirty-sixth stomach acupoint of the meridian acupoints. This location is called "Zusanli" (ST36) and is located along the outer boundary of the tibia, four fingers wide down the bottom of the knee. As shown in fig. 10, the "SP point" is a point where a vertical line "a" extending from the center of the pupil of the left or right eye intersects with a horizontal line "b" extending at an intermediate height between the lowest part of the nose and the highest part of the upper lip. The vertical line "a" may be set to one or each eye of the left and right eyes to set two SP points.
In this particular example, the stimulus application device is used to apply a stimulus (such as heat, light, sound waves, vibration, pressure stimulus, etc.) to the site. The method can promote growth hormone secretion of individuals with reduced hormone secretion with aging, and simultaneously stimulate outer membrane of lens.
In ocular treatment, preferably, the stimulus is applied simultaneously to: (1): (F) the intersection of the medial malleolar vertical line in the left or right foot with the extension of the medial border on the 1 st and 2 nd metatarsals, (2): pupil 103(EY) of left or right eye 104; (3): ST36 point of left or right leg; and (4): SP wells, lasting about 30 to 45 minutes.
A stimulation application device for eye treatment has two or more guide elements made of two different kinds of metals. The guiding elements are provided on the respective specific site to be stimulated and heated to a temperature of about 40 to 50 ± 5 ℃, thereby directly or indirectly providing the thermal stimulation to the skin surface of the stimulation site or the stimulation site. The guide elements are preferably made of at least two different kinds of metals and/or ceramics, such as aluminium and steel. One or more of the guide elements may comprise a ceramic. For example, the pupil is closed, an adhesive tape is attached to the center of the pupil, and a guide member (electrode) is attached to the surface of the adhesive tape at the position of the center of the pupil, and then power is applied to the guide member so that current flows through the guide member including metal, thereby increasing the temperature thereof for about 30 to 45 minutes while the guide member including ceramic is irradiated with infrared light.
The electrical warm-temperature heating apparatus and the method of controlling the apparatus disclosed in the present application may be used in eye treatment.
Preferably, heat stimulus, light stimulus, vibration stimulus, etc., and any combination thereof are simultaneously applied to the above-mentioned stimulus application site in such a manner and amount as to effectively promote secretion of growth hormone by an individual whose hormone secretion is decreased with age, while it stimulates the outer membrane of the crystalline lens and at the same time accelerates the metabolism of the crystalline lens.
In a method of ocular treatment using a thermal stimulus application apparatus as described above, application of a thermal stimulus in the range of 40 to 50 ± 5 ℃ may be applied to the stimulation site such that it increases blood flow by 60% or more in order to promote secretion of growth hormone by the individual.
The method of eye treatment according to the invention can also be carried out in the following manner. The predetermined thermal stimulation pattern is stored in the memory unit. Two or more guide elements made of two different kinds of metals are respectively made on at least two different specific portions including the portions (1) to (4), preferably all the portions (1) to (4). Reading out a thermal stimulation pattern from the memory cell; and outputting a thermal stimulation pattern to the two or more guide elements such that the temperature of the two or more guide elements is heated to within 40 to 50 ± 5 ℃; whereby thermal stimulation is applied to respective specific portions according to a thermal stimulation pattern so as to increase blood flow by 60% or more by applying the thermal stimulation.
Claims (8)
1. A method for ocular treatment by applying stimulation to a specific site of an individual with a stimulation application device, the method comprising:
providing two or more guide members made of two different kinds of metals on the specific parts, respectively, the specific parts including (1) a part where a vertical line of a medial malleolus intersects with an extension line of a medial edge on a 1 ST metatarsal (OS metasale primum) and a 2 nd metatarsal, (2) a pupil of a left or right eye, (3) an ST36 hole of a left or right leg, and (4) an SP hole where a vertical line extending from a center of the pupil intersects with a horizontal line extending at a middle height between a lowest part of a nose and a highest part of an upper lip; and
controlling the temperature of the guide member within a range of 40 to 50 + -5 deg.C, thereby applying the thermal stimulation to the specific part according to a thermal stimulation pattern so as to increase the blood flow of the individual by 60% or more by applying the thermal stimulation.
2. The method of claim 1, wherein the stimulating of the pupil is performed by: closing the pupil, attaching an adhesive tape to the center of the pupil, attaching the guiding element to the surface of the adhesive tape at the center of the pupil, and applying power to the guiding element, thereby increasing the temperature of the guiding element.
3. The method of claim 1 or 2, wherein the guiding element further comprises a ceramic such that infrared light is irradiated from the guiding element.
4. The method of any one of claims 1-3, wherein the stimulus comprises at least one of a thermal stimulus, a light stimulus, and a vibration stimulus.
5. The method of any one of claims 1-4, wherein the ocular treatment is performed while also accelerating metabolism of a lens of the eye.
6. The method of any one of claims 1-5, wherein the ocular treatment promotes secretion of growth hormone by individuals with reduced hormone secretion with age while stimulating the outer membrane of the lens of the eye.
7. The method of any one of claims 1-6, wherein the ocular treatment is treatment of at least one of cataract, presbyopia, myopia, and astigmatism.
8. The method of any one of claims 1 to 7, further comprising:
storing the thermal stimulation pattern in a memory unit;
-placing the two or more guiding elements on at least two different specific locations of the specific locations (1) to (4), respectively;
reading out the thermal stimulation pattern from the memory cell;
controlling the temperature of the two or more guide elements within the range of 40 to 50 ± 5 ℃; and
outputting the thermal stimulation pattern to the two or more guide elements, whereby the thermal stimulation is applied to the respective specific sites simultaneously according to the thermal stimulation pattern so as to increase the blood flow by 60% or more by applying the thermal stimulation.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/021,434 | 2020-09-15 | ||
US17/021,434 US11766351B2 (en) | 2011-07-18 | 2020-09-15 | Stimulus method for promoting secretion of growth hormone |
US17/198,648 US20210196505A1 (en) | 2011-07-18 | 2021-03-11 | Stimulus method for eye treatment |
US17/198,648 | 2021-03-11 | ||
PCT/IB2021/055371 WO2022058802A1 (en) | 2020-09-15 | 2021-06-17 | Stimulus method for eye treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114786631A true CN114786631A (en) | 2022-07-22 |
Family
ID=80775959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180006284.3A Pending CN114786631A (en) | 2020-09-15 | 2021-06-17 | Stimulation method for eye treatment |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2023540978A (en) |
CN (1) | CN114786631A (en) |
TW (1) | TWI810647B (en) |
WO (1) | WO2022058802A1 (en) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001327614A (en) * | 2000-03-16 | 2001-11-27 | Seputo:Kk | Near infrared therapeutic instrument with heater |
JP3092678U (en) * | 2002-09-09 | 2003-03-20 | 株式会社サカキバラテック | Heating equipment |
JP2004350803A (en) * | 2003-05-28 | 2004-12-16 | Hasegawa Tokuichiro | Eye mask and visual acuity correcting jig |
US20090043365A1 (en) * | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
US20130041396A1 (en) * | 2011-07-18 | 2013-02-14 | Kenji Ryotokuji | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method |
US20140200544A1 (en) * | 2011-08-22 | 2014-07-17 | Kenji Ryotokuji | Drug supply start timing determination method and drug conveyance system |
US20150094671A1 (en) * | 2005-02-08 | 2015-04-02 | Carewave, Inc. | Apparatus and method for using a portable thermal device to reduce accommodation of nerve receptors |
US20160058610A1 (en) * | 2011-07-18 | 2016-03-03 | Kenji Ryotokuji | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method |
US20160199219A1 (en) * | 2011-07-18 | 2016-07-14 | Kenji Ryotokuji | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method |
US20160242954A1 (en) * | 2011-07-18 | 2016-08-25 | Kenji Ryotokuji | Method of controlling immune cells |
US20170274173A1 (en) * | 2016-03-23 | 2017-09-28 | Kenji Ryotokuji | Stimulation application apparatus |
US20190151139A1 (en) * | 2012-02-24 | 2019-05-23 | Kenji Ryotokuji | Method for conducting stimulus treatment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120041859A (en) * | 2010-10-22 | 2012-05-03 | 최옥용 | A eye healing omitted |
CN206275825U (en) * | 2016-07-05 | 2017-06-27 | 黎熙 | A kind of instrument for eye disease of cooperation human eye movement |
CN209378030U (en) * | 2018-08-08 | 2019-09-13 | 郑州华厦眼科医院有限公司 | A kind of xerophthalmia acupoint-physiotherapeutic instrument |
-
2021
- 2021-06-17 CN CN202180006284.3A patent/CN114786631A/en active Pending
- 2021-06-17 WO PCT/IB2021/055371 patent/WO2022058802A1/en active Application Filing
- 2021-06-17 JP JP2023514908A patent/JP2023540978A/en active Pending
- 2021-09-09 TW TW110133586A patent/TWI810647B/en active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001327614A (en) * | 2000-03-16 | 2001-11-27 | Seputo:Kk | Near infrared therapeutic instrument with heater |
JP3092678U (en) * | 2002-09-09 | 2003-03-20 | 株式会社サカキバラテック | Heating equipment |
JP2004350803A (en) * | 2003-05-28 | 2004-12-16 | Hasegawa Tokuichiro | Eye mask and visual acuity correcting jig |
US20150094671A1 (en) * | 2005-02-08 | 2015-04-02 | Carewave, Inc. | Apparatus and method for using a portable thermal device to reduce accommodation of nerve receptors |
US20090043365A1 (en) * | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
US20130041396A1 (en) * | 2011-07-18 | 2013-02-14 | Kenji Ryotokuji | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method |
US20160058610A1 (en) * | 2011-07-18 | 2016-03-03 | Kenji Ryotokuji | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method |
US20160199219A1 (en) * | 2011-07-18 | 2016-07-14 | Kenji Ryotokuji | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method |
US20160242954A1 (en) * | 2011-07-18 | 2016-08-25 | Kenji Ryotokuji | Method of controlling immune cells |
US20140200544A1 (en) * | 2011-08-22 | 2014-07-17 | Kenji Ryotokuji | Drug supply start timing determination method and drug conveyance system |
US20190151139A1 (en) * | 2012-02-24 | 2019-05-23 | Kenji Ryotokuji | Method for conducting stimulus treatment |
US20170274173A1 (en) * | 2016-03-23 | 2017-09-28 | Kenji Ryotokuji | Stimulation application apparatus |
Also Published As
Publication number | Publication date |
---|---|
WO2022058802A1 (en) | 2022-03-24 |
JP2023540978A (en) | 2023-09-27 |
TWI810647B (en) | 2023-08-01 |
TW202220634A (en) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2783067C (en) | Heat stimulus applying apparatus | |
US20230044828A1 (en) | Therapeutic muscle stimulation such as for lymphedema | |
US9731107B2 (en) | Treatment | |
US9370620B2 (en) | Drug supply start timing determination method and drug conveyance system | |
JP2019510529A (en) | Systems, methods and devices for peripheral neuromodulation for treating diseases associated with overactive bladder | |
JP2008520306A (en) | apparatus | |
Takayama et al. | Brief effect of acupuncture on the peripheral arterial system of the upper limb and systemic hemodynamics in humans | |
US10828188B2 (en) | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method | |
US11173273B2 (en) | Stimulation application apparatus | |
US10420673B2 (en) | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method | |
US11766351B2 (en) | Stimulus method for promoting secretion of growth hormone | |
US10213333B2 (en) | Method of controlling immune cells | |
US11857784B2 (en) | Method for conducting stimulus treatment | |
JP6373647B2 (en) | Ultrasonic irradiation apparatus and diagnostic system | |
TWI810647B (en) | Stimulus method for eye treatment | |
US20210196505A1 (en) | Stimulus method for eye treatment | |
JP2023509244A (en) | Acupuncture point stimulation device and acupuncture point stimulation method using the same | |
US20160199218A1 (en) | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method | |
US20170079878A1 (en) | Stimulation application apparatus | |
US20150305924A1 (en) | Stimulus method for releasing stress, and stress-free medical treatment method by the stimulus method | |
JP2013233416A (en) | Ultrasonic irradiation apparatus and diagnostic system | |
JP2018089372A (en) | Stimulating device | |
KR20210090910A (en) | Apparatus for controlling blood pressure using device of stimulating acupoint and method for controlling blood pressure using it | |
JP2014155581A (en) | Heat stimulus transmission evaluation method and evaluation method of drug benefit by thermal stimulus transmission | |
Huang et al. | Responses of the sympathetic nervous system during fever induced by intracerebroventricular injection of thyrotropin-releasing hormone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |